Russell Investments Group Ltd. Cuts Stock Position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Russell Investments Group Ltd. lessened its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 11.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 140,496 shares of the specialty pharmaceutical company's stock after selling 17,462 shares during the period. Russell Investments Group Ltd. owned 0.67% of ANI Pharmaceuticals worth $7,767,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. US Bancorp DE grew its stake in shares of ANI Pharmaceuticals by 842.9% in the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares during the last quarter. KBC Group NV boosted its stake in ANI Pharmaceuticals by 89.2% in the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in ANI Pharmaceuticals during the 4th quarter valued at about $166,000. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter valued at about $222,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in ANI Pharmaceuticals by 10.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after buying an additional 412 shares during the last quarter. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock traded up $0.01 during mid-day trading on Friday, reaching $69.21. 299,660 shares of the company's stock traded hands, compared to its average volume of 270,846. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The firm has a market capitalization of $1.51 billion, a PE ratio of -125.84 and a beta of 0.49. ANI Pharmaceuticals, Inc. has a 12 month low of $52.50 and a 12 month high of $70.48. The firm has a 50 day moving average price of $63.07 and a two-hundred day moving average price of $59.36.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction on Friday, February 21st. The shares were sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. This represents a 1.44 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Meredith Cook sold 400 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total value of $25,332.00. Following the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,200 shares of company stock valued at $197,792. Company insiders own 12.70% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Guggenheim reissued a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a research report on Friday, April 11th. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. JPMorgan Chase & Co. began coverage on ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 target price for the company. Finally, StockNews.com raised shares of ANI Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $79.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.